Department of Anorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Research Article
Constructing the Immune Related Prognosis Score to Predict the Benefit of Immunotherapy in Colorectal Cancer
Author(s): Jun Xiang, JunHu Li, XiaoNan Cheng, HanQing Hu, Lei Yu* and GuiYu Wang*
Background: Since Food and Drug Administration (FDA) approved immune checkpoint inhibitors for the
treatment of colorectal cancer in 2017, there have been significant differences in the response of colorectal cancer
patients to immune checkpoint inhibitors. In order to achieve better clinical benefits of colorectal cancer patients
in immunotherapy, we urgently need to find a biomarker to evaluate whether colorectal cancer patients respond
to immunotherapy. In this research, we aimed to explore a biomarker to predict the efficacy of immunotherapy for
colorectal cancer patients.
Materials and methods: We collected the expression profiles and clinical information of more than 1800 colorectal
cancer patients in 6 cohorts in Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA)
databases and meanwhile, we collected 2.. View More»
DOI:
10.35248/IGOA.23.8.199